Oncolys BioPharma Cash Flow Statement

Financials in millions JPY. Fiscal year is January - December.

Millions JPY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Net Income	-1,685	-1,939	-1,149	-1,615	-2,095
Depreciation & Amortization	0.82	2.29	0.91	6.49	4.89
Other Amortization	-	8.78	-	-	-
Loss (Gain) From Sale of Assets	-	-	-	90.98	-
Asset Writedown & Restructuring Costs	17.1	21.9	4.4	19.85	11.14
Loss (Gain) From Sale of Investments	-	-	-21.41	-	321
Stock-Based Compensation	25.63	10.06	75.93	277.48	390.51
Provision & Write-off of Bad Debts	-	-	-	-	35.68
Other Operating Activities	-9.85	6.15	-71.31	-41.75	16.91
Change in Accounts Receivable	-	-	352.15	-281.55	98.71
Change in Inventory	0.76	18.91	-12.59	-1.18	4.44
Change in Accounts Payable	-141.35	132.73	-45.37	-100.34	-60.9
Change in Unearned Revenue	-	-	-285.76	-	-
Change in Other Net Operating Assets	-228.42	400.78	-565.15	-96.36	-192.5
Operating Cash Flow	-2,020	-1,337	-1,717	-1,742	-1,465
Capital Expenditures	-3.52	-5.69	-1.36	-1.44	-2.7
Sale of Property, Plant & Equipment	-	0.14	-	-	-
Cash Acquisitions	-	-	-	-	-10.76
Investment in Securities	-0	-0	21.41	0.49	-0.01
Other Investing Activities	-1.19	0.16	0.07	0.01	-2.35
Investing Cash Flow	-4.71	-5.39	20.12	-0.94	-37.58
Long-Term Debt Issued	100	100	100	100	100
Short-Term Debt Repaid	-	-	-100	-	-
Long-Term Debt Repaid	-106.37	-198.98	-113.77	-124.84	-103.15
Total Debt Repaid	-106.37	-198.98	-213.77	-124.84	-103.15
Net Debt Issued (Repaid)	-6.37	-98.98	-113.77	-24.84	-3.15
Issuance of Common Stock	2,891	1,242	-	3,128	245.51
Repurchase of Common Stock	-5	-	-0.03	-0.04	-0.1
Other Financing Activities	-0	-	-0.03	-12.07	-0
Financing Cash Flow	2,879	1,143	-113.83	3,091	242.26
Foreign Exchange Rate Adjustments	23.5	21.33	67.41	38.17	-14.15
Miscellaneous Cash Flow Adjustments	-	-	0	-0	-0
Net Cash Flow	878.16	-178.44	-1,743	1,387	-1,275
Free Cash Flow	-2,024	-1,343	-1,718	-1,743	-1,468
Free Cash Flow Margin	-6447.89%	-2129.84%	-176.04%	-271.33%	-467.22%
Free Cash Flow Per Share	-92.69	-75.44	-99.18	-103.06	-102.00
Cash Interest Paid	4.34	3.84	3.96	4.19	4.32
Cash Income Tax Paid	2.94	-25.37	1.47	3.73	3.73
Levered Free Cash Flow	-1,428	-566.1	-943.47	-1,012	-788.94
Unlevered Free Cash Flow	-1,425	-563.85	-941.01	-1,009	-786.34
Change in Working Capital	-369.01	552.41	-556.72	-479.43	-150.24

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.